Journal of Neural Transmission (2024) 131:505–508 https://doi.org/10.1007/s00702-023-02734-2 PSYCHIATRY AND PRECLINICAL PSYCHIATRIC STUDIES - SHORT COMMUNICATION Driving innovation in addiction treatment: role of transcranial magnetic stimulation Graziella Madeo1 · Antonello Bonci1,2 Received: 29 October 2023 / Accepted: 20 December 2023 / Published online: 17 January 2024 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2024 Abstract Addictions comprises heterogenous psychiatric conditions caused by the complex interaction of genetic, neurobiological, psychological, and environmental factors with a chronic relapsing-remitting pattern. Despite the long-standing efforts of preclinical and clinical research studies, addiction field has seen relatively slow progress when it comes to the development of new therapeutic interventions, most of which failed to demonstrate a significant efficacy. This is likely due to the very complex interplay of many factors that contribute to both the development and expression of addictions. The imbalance between the salience and the reward brain network circuitry has been proposed as the neurobiological mechanisms explaining the pathognomonic symptoms of addictions.Non-invasive neuromodulation techniques have been proposed as a promising therapeutic intervention to restore these brain circuits dysfunctions. Here, we propose a multi-level strategy to innovate the diagnosis and the treatment of addictive disorders. Keywords Addiction · Reward · Non-invasive brain stimulation · Transcranial magnetic stimulation · Brain plasticity Addictions comprise heterogenous psychiatric conditions caused by the complex interaction of genetic, neurobiological, psychological, and environmental factors with a chronic relapsing–remitting pattern. Addictive disorders remain at a global level a significant socioeconomic burden representing one of the main causes of decreasing disability-adjusted life years (Rate of Disease Burden from Drug Use Disorders 2019). According to the latest World Drug Report of 2021, 296 million people, or approximately 5.8% of the global adult population aged 15–64 years, used illicit drugs at least once, with an increase of 23% in the last 10 years (World Drug Report, Executive Summary 2023). In 2021 alone, the harm caused by drug use led to an estimated 28 million years of healthy life lost worldwide as a result of premature death and disability. Cannabis remains the most consumed drug worldwide, but opioids hold the place as the most harmful drugs accounted for nearly 70% of the 128,000 deaths attributed to drug use disorders in 2019 ( World Drug Report, Executive Summary 2023). * Graziella Madeo [email protected] 1 Brain & Care Group, Rimini, Italy 2 GIA Healthcare, 1501 Biscayne Blvd, Miami 33137, USA Despite the long-standing efforts of preclinical and clinical research studies, the addiction field has seen relatively slow progress when it comes to the development of new therapeutic interventions, most of which failed to demonstrate significant efficacy. This is likely due to the very complex interplay of many factors that contribute to both the development and expression of addictions. Indeed, the current approach to addictions involves psychosocial and pharmacological interventions (Brooks and Mchenry 2023). To note, some addictions to substances like cannabis and cocaine are still “orphan” in the sense that they do not have targeted pharmacological treatment (Douaihy et al. 2013). In the case of alcohol, however, medications with an anticraving effect do exist but have limited efficacy (Burnette et al. 2022). One of the main problems in finding effective molecular targets for pharmacological treatments is linked to the complex pathophysiological alterations underlying addiction. Decades of preclinical and clinical research have allowed a better comprehension of the brain circuits changes occurring within the salience and reward networks leading to the widely accepted concept that addiction is a brain disease (Goldstein and Volkow 2011; Koob and Volkow 2016). The salience and the reward networks involve brain areas such as dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex, insula, ventromedial prefrontal cortex Vol.:(0123456789) 506 (VMPFC), orbitofrontal cortex, and nucleus accumbens, which are implicated in the cognitive control and response inhibition of actions, as well as reward-related behaviors (Dosenbach et al. 2006; Menon and Uddin 2010; Volkow et al. 2011). The dynamic imbalance between these two circuits is thought to be one of the main dysfunctions leading to poor cognitive control in the decision-making process and the powerful desire to consume addictive substances (Hu et al. 2015). This imbalance offers not only an explanation for the most pathognomonic symptoms of addictions, the uncontrolled compulsive consumption of drug and the incoercible craving but also the basis for developing therapeutic strategies aiming at reinforcing the salience network to improve cognitive control and inhibiting the overactive reward pathway to negatively impact on craving. Looking at the neurobiology of addiction, neuromodulation techniques have been proposed as a promising therapeutic intervention to restore brain circuits dysfunctions. Particularly, non-invasive brain stimulation techniques, such as transcranial magnetic stimulation (TMS) has the ability to modulate circuit network activity through the plasticity changes within key brain areas (Diana et al. 2017; Ekhtiari et al. 2019). These techniques, particularly TMS, have already obtained the American Federal Drug Administration (FDA) and European regulatory agency approval for the treatment of other psychiatric conditions, such as resistant major depressive disorder, obsessive–compulsive disorder, and more recently for smoking cessation (Cohen et al. 2022; Johnson et al. 2013). In 2021, TMS has also received the European CE mark for the treatment of psychoactive substances use disorders (Cotovio et al. 2023). Regarding TMS, the ability to modulate brain activity with long-lasting effects is based on the generation of brief and intense magnetic pulses producing a secondary electrical current in the brain, which in turn modifies the cortical excitability of the cerebral cortex area where the pulses are directed (Diana et al. 2017). There are several types of TMS modalities: single, paired and repetitive. Single and paired modalities are mainly used for diagnostic purposes, whereas repetitive patterns are applied for therapeutic intervention due to their ability to induce long-term changes in synaptic plasticity (Hallett 2007). So far clinical studies have explored the efficacy of TMS in addictions using two main approaches. One approach focused on reinforcing key brain areas in the salience network by using excitatory stimulation protocols, such as the DLPFC, that should increase the cognitive control of individuals with addiction (Dunlop et al. 2017; Hanlon et al. 2015). Targeting DLPFC with excitatory stimulation protocols has been associated with a significant reduction in cigarette smoking (Dinur-Klein et al. 2014; Zangen et al. 2021), or other drug consumption like cocaine (Madeo et al. 2020; Steele et al. 2019; Lolli et al. 2021; Scarpino et al. 2019; Garza-Villarreal et al. 2021). Using Deep TMS coils, G. Madeo, A. Bonci allowing the simultaneous stimulation of several brain areas, including DLPFC and insula, similar effects on the reduction of drug consumption have been obtained (Dinur-Klein et al. 2014; Suñer-Soler et al. 2022). The complementary approach focusing on the reward circuit has targeted the VMPFC to attenuate craving (Hanlon et al. 2013). However, studies focusing on the efficacy of anti-craving interventions have shon a great level of variability in response suggesting that the observed effects may depend on various psychoneuro-biological factors (Kearney-Ramos et al. 2019). Studies using TMS combined withneuroimaging have shown several biological factors contributing to individual variability, including differences in the activation of intracortical networks (Hamada et al. 2013), in the resting state connectivity between brain nodes (Nettekoven et al. 2015), in cortical excitability (Jannati et al. 2017), and genetic background (Abellaneda-Pérez et al. 2019). Technical advances in TMS procedures, involving new coils, protocol parameters, neuro navigation software, and the combination of TMS with other advanced tools, like neuroimaging or neurophysiology, will allow a better and deeper understanding of the neurobiology underlying the individual variability seen in people with addiction with diagnostic, therapeutic, and prognostic implications. The idea is that neuromodulation protocols may help maximize treatment success. Furthermore, it is important to mention that the variability seen across the studies focusing on the TMS efficacy for addiction treatment, does not take into account the intersubject variability, such as distinct personality traits, the level of expression of co-morbidities, personal history, and environmental factors. In this framework, we wish to emphasize that non-invasive neuromodulation should be implemented in clinical practice as adjunctive intervention, combined with traditional pharmacotherapy and psychosocial support in the vast majority of cases. This may sound a bit forward, but this idea is based on the fact that the majority of these patients often manifest co-morbidities, such as anxiety, post-traumatic stress disorder (PTSD), depression, insomnia, or obsessive–compulsive disorder (OCD), all conditions where TMS can also help medications (when in existence) as well as compliance to psychological therapy. Finally, using this approach, clinicians will have a strong opportunity to better identify biomarkers helping the diagnostic characterization and the prediction of response to a specific treatment. Novel and additional approaches such as TMS are needed in the addiction field to carry forward a concrete and efficacious precision medicine-based intervention. To achieve this goal, two parallel levels of work should be carried out. First, clinicians should disentangle the complex co-morbidities, often associated with addiction and tackle Driving innovation in addiction treatment: role of transcranial magnetic stimulation the social components contributing to the persistence of the disorder. In this view, with a transversal effort, clinical centers, academic institutions, and scientific associations should work together to harmonize data collection, clinical assessment, and general protocol of interventions. If data harmonization is not feasible in the short-term, fast-track avenues for publishing non-harmonized clinical data should also be readily available to clinicians, provided careful and rigorous data quality control. The second level of work should focus on improving the application of neuroimaging and/or neurophysiological techniques to identify the specific brain networks that need to be stimulated/inhibited/modulated to achieve a reduction of craving and increase the cognitive control of patients with substance use disorders and addictions. In conclusion, in addiction medicine, non-invasive neuromodulation, psychological interventions along neuropharmacological agents represent the most successful multi-level strategy to treat and target the neurobiological underpinning of addiction. This multilevel strategy could also help identify biomarkers of individual variability and to tackle the complex comorbidities present in the majority of these patients, leading to both a personalized and a comprehensive therapeutic approach. This approach in treating people struggling with addiction needs to be pursued along with a focus on prevention, involvement of patients and relatives, and a proactive attitude from scientists and clinicians. Data availability Not applicable. References Abellaneda-Pérez K, Vaqué-Alcázar L, Vidal-Piñeiro D, Jannati A, Solana E, Bargalló N et al (2019) Age-related differences in default-mode network connectivity in response to intermittent theta-burst stimulation and its relationships with maintained cognition and brain integrity in healthy aging. Neuroimage 188:794–806 Brooks F, Mchenry B. Substance use disorders and addiction counseling. www.counseling.org. Cited 27 Oct 2023 Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K et al (2022) Novel agents for the pharmacological treatment of alcohol use disorder. Drugs 82:251 Cohen SL, Bikson M, Badran BW, George MS (2022) A visual and narrative timeline of US FDA milestones for transcranial magnetic stimulation (TMS) devices. Brain Stimul 15:73–75 Cotovio G, Ventura F, da Silva DR, Pereira P, Oliveira-Maia AJ (2023) Regulatory clearance and approval of therapeutic protocols of transcranial magnetic stimulation for psychiatric disorders. Brain Sci 13:1029 Diana M, Raij T, Melis M, Nummenmaa A, Leggio L, Bonci A (2017) Rehabilitating the addicted brain with transcranial magnetic stimulation. Nat Rev Neurosci 18:685–693 Dinur-Klein L, Dannon P, Hadar A, Rosenberg O, Roth Y, Kotler M et al (2014) Smoking cessation induced by deep repetitive 507 transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry Elsevier 76:742–749 Dosenbach NUF, Visscher KM, Palmer ED, Miezin FM, Wenger KK, Kang HC et al (2006) A core system for the implementation of task sets. Neuron 50:799–812 Douaihy AB, Kelly TM, Sullivan C (2013) Medications for substance use disorders. Soc Work Public Health 28:264 Dunlop K, Hanlon CA, Downar J (2017) Noninvasive brain stimulation treatments for addiction and major depression. Ann N Y Acad Sci 1394:31–54 Ekhtiari H, Tavakoli H, Addolorato G, Baeken C, Bonci A, Campanella S et al (2019) Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: a consensus paper on the present state of the science and the road ahead. Neurosci Biobehav Rev 104:118–140 World Drug Report, Executive Summary 2023. www.u nodc.o rg/u nodc/ en/data-and-analysis/world-drug-report-2023.html. Cited 27 Oct 2023 Garza-Villarreal EA, Alcala-Lozano R, Fernandez-Lozano S, Morelos-Santana E, Dávalos A, Villicaña V et al (2021) Clinical and functional connectivity outcomes of 5-Hz repetitive transcranial magnetic stimulation as an add-on treatment in cocaine use disorder: a double-blind randomized controlled trial. Biol Psychiatry Cogn Neurosci Neuroimaging 6:745–757 Goldstein RZ, Volkow ND (2011) Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 12:652–669 Hallett M (2007) Transcranial magnetic stimulation: a primer. Neuron 55:187–199 Hamada M, Murase N, Hasan A, Balaratnam M, Rothwell JC (2013) The role of interneuron networks in driving human motor cortical plasticity. Cereb Cortex 23:1593–1605 Hanlon CA, Hartwell KJ, Canterberry M, Li X, Owens M, LeMatty T et al (2013) Reduction of cue-induced craving through realtime neurofeedback in nicotine users: the role of region of interest selection and multiple visits. Psychiatry Res 213:79–81 Hanlon CA, Dowdle LT, Austelle CW, Devries W, Mithoefer O, Badran BW et al (2015) What goes up, can come down: novel brain stimulation paradigms may attenuate craving and cravingrelated neural circuitry in substance dependent individuals. Brain Res 1628:199–209 Hu Y, Salmeron BJ, Gu H, Stein EA, Yang Y (2015) Impaired functional connectivity within and between frontostriatal circuits and its association with compulsive drug use and trait impulsivity in cocaine addiction. JAMA Psychiat 72:584–592 Jannati A, Block G, Oberman LM, Rotenberg A, Pascual-Leone A (2017) Interindividual variability in response to continuous theta-burst stimulation in healthy adults. Clin Neurophysiol 128:2268–2278 Johnson MD, Lim HH, Netoff TI, Connolly AT, Johnson N, Roy A et al (2013) Neuromodulation for brain disorders: challenges and opportunities. IEEE Trans Biomed Eng 60:610–624 Kearney-Ramos TE, Dowdle LT, Mithoefer OJ, Devries W, George MS, Hanlon CA (2019) State-dependent effects of ventromedial prefrontal cortex continuous thetaburst stimulation on cocaine cue reactivity in chronic cocaine users. Front Psychiatry. 10:453449 Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3:760–773 Lolli F, Salimova M, Scarpino M, Lanzo G, Cossu C, Bastianelli M et al (2021) A randomised, double-blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine consumption and craving. PLoS ONE 16:e0259860 Madeo G, Terraneo A, Cardullo S, Gómez Pérez LJ, Cellini N, Sarlo M et al (2020) Long-term outcome of repetitive transcranial 508 magnetic stimulation in a large cohort of patients with cocaineuse disorder: an observational study. Front Psychiatry 11:00158 Menon V, Uddin LQ (2010) Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct 214:655 Nettekoven C, Volz LJ, Leimbach M, Pool EM, Rehme AK, Eickhoff SB et al (2015) Inter-individual variability in cortical excitability and motor network connectivity following multiple blocks of rTMS. Neuroimage 118:209–218 Rate of disease burden from drug use disorders, 2019. https://ourwo rldind ata.o rg/g raphe r/d rug-d isord er-d alys-r ate. Cited 27 Oct 2023 Scarpino M, Lanzo G, Salimova M, Lolli F, del Vecchio A, Cossu C et al (2019) Efficacy of high-frequency (15 Hz) repetitive transcranial magnetic stimulation (rTMS) of the left premotor cortex/ dorsolateral prefrontal cortex in decreasing cocaine intake (the MagneTox study): a study protocol for a randomized placebocontrolled pilot trial. Neurophysiol Clin 49:1–9 Steele VR, Maxwell AM, Ross TJ, Stein EA, Salmeron BJ (2019) Accelerated intermittent theta-burst stimulation as a treatment for cocaine use disorder: a proof-of-concept study. Front Neurosci 13:01147 G. Madeo, A. Bonci Suñer-Soler R, Grau-Martín A, Tercenõ M, Silva Y, Maldonado E, Gras ME et al (2022) A clinical trial comparing smoking cessation interventions at two levels of intensity in stroke patients, stratified by the presence of insular cortex lesions. Nicotine Tob Res 24:44–52 Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F (2011) Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A 108:15037–15042 Zangen A, Moshe H, Martinez D, Barnea-Ygael N, Vapnik T, Bystritsky A et al (2021) Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry 20:397–404 Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Puede agregar este documento a su colección de estudio (s)
Iniciar sesión Disponible sólo para usuarios autorizadosPuede agregar este documento a su lista guardada
Iniciar sesión Disponible sólo para usuarios autorizados(Para quejas, use otra forma )